TY  - JOUR
AU  - Reck, Martin
AU  - Paz-Ares, Luis
AU  - Bidoli, Paolo
AU  - Cappuzzo, Federico
AU  - Dakhil, Shaker
AU  - Moro-Sibilot, Denis
AU  - Borghaei, Hossein
AU  - Johnson, Melissa
AU  - Jotte, Robert
AU  - Pennell, Nathan A
AU  - Shepherd, Frances A
AU  - Tsao, Anne
AU  - Thomas, Michael
AU  - Carter, Gebra Cuyun
AU  - Chan-Diehl, Faye
AU  - Alexandris, Ekaterine
AU  - Lee, Pablo
AU  - Zimmermann, Annamaria
AU  - Sashegyi, Andreas
AU  - Pérol, Maurice
PY  - 2017
DO  - 10.1016/j.lungcan.2017.07.038
UR  - http://hdl.handle.net/10668/11859
T2  - Lung cancer (Amsterdam, Netherlands)
AB  - The REVEL study demonstrated improved efficacy for patients with advanced non-small cell lung cancer treated with ramucirumab plus docetaxel, independent of histology. This exploratory analysis characterized the treatment effect in REVEL patients who...
LA  - en
KW  - Angiogenesis
KW  - Clinical trial
KW  - Docetaxel
KW  - Histology
KW  - Human monoclonal antibody
KW  - Non-small cell lung cancer (NSCLC)
KW  - Phase 3 clinical trial
KW  - Ramucirumab
KW  - Refractory patients
KW  - Vascular endothelial growth factor (VEGF)
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antibodies, Monoclonal
KW  - Antibodies, Monoclonal, Humanized
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Carcinoma, Non-Small-Cell Lung
KW  - Disease Progression
KW  - Docetaxel
KW  - Drug Resistance, Neoplasm
KW  - Female
KW  - Humans
KW  - Kaplan-Meier Estimate
KW  - Lung Neoplasms
KW  - Male
KW  - Middle Aged
KW  - Neoplasm Staging
KW  - Quality of Life
KW  - Retreatment
KW  - Taxoids
KW  - Treatment Outcome
KW  - Young Adult
TI  - Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer.
TY  - research article
VL  - 112
ER  -